[Transitional cell carcinoma of the ovary: one kind of uncommon type of ovarian epithelial carcinoma].
OBJECTIVE
To evaluated clinico-biologic behavior, prognosis and relative prognostic factors of transitional cell carcinoma of the ovary.


METHODS
The clinical records of 58 patients with transitional cell carcinoma of the ovary, who received treatment in the department of Obstetrics and Gynecology, Peking Union Medical College Hospital in 20 years, were reviewed retrospectively. The data were analyzed statistically by SPSS 10.0.


RESULTS
Among 58 cases, the median age was 55 +/- 10 (35 - 75) years old. 31% of them had bilateral ovary involvement, and the median level of CA(125) was (687 +/- 365) U/L. All patients received cytoreductive surgery in our hospital, 69% of them got optimal cytoreduction. Pathologic results showed that G(1), G(2), G(3) were 7%, 45% and 48% respectively, 40% were demonstrated lymph node metastasis. Nearly 80% of patients were classified to International Federation of Gynecology and Obstetrics (FIGO) stage III and IV. Different courses of chemotherapy were given to all patients. The recurrence occurred in 45% of cases and the death rate was 53%. The Cox hazards regression model was used to analyze the possible prognostic factors and revealed that tumor residuals (P < 0.01), preoperative level of CA(125) (P < 0.01), bilateral ovary involvement (P < 0.05) and lymph node metastasis (P < 0.05) were the most important prognostic factors.


CONCLUSIONS
Transitional cell carcinoma of ovary is an uncommon type of ovarian cancer. It usually behaves better prognosis when compared with papillary serous cystadenocarcinoma of the ovary.
Wu
Ming
M
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
Shen
Keng
K
Lang
Jinghe
J
Huang
Rongli
R
Huang
Huifang
H
Pan
Lingya
L
D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D015996:Survival Rate